Literature DB >> 12393436

Abnormal T cell-dependent B-cell responses in SCID mice receiving allogeneic bone marrow in utero. Severe combined immune deficiency.

Thomas J Waldschmidt1, Angela Panoskaltsis-Mortari, Ronald T McElmurry, Lorraine T Tygrett, Patricia A Taylor, Bruce R Blazar.   

Abstract

In allogeneic hematopoietic stem cell transplant recipients, restoration of humoral immunity is delayed and can remain impaired for years. In many severe combined immune deficiency (SCID) patients given haploidentical bone marrow (BM), lesions in humoral immunity are exacerbated by poor engraftment of donor B cells. The nature of these defects is important to understand as they render patients susceptible to infection. Previous work in mice suggested that in utero transplantation (IUT) of allogeneic BM might offer several advantages for the correction of primary immune deficiencies. In SCID mice given fully allogeneic BM in utero, the lymphoid compartment was restored with minimal evidence of graft-versus-host disease (GVHD). The present report examines B-cell reconstitution and function in mice that have received allogeneic IUT. Results are compared with those of adult mice given total body irradiation (TBI) followed by transplantation with allogeneic BM. In addition to enumerating the various B-cell subsets present in BM, spleen, and peritoneal cavity (PC), B-cell competence was assessed by challenging mice with T cell-independent (TI) and T cell-dependent (TD) antigens. The results demonstrated that all B-cell subsets in the BM and periphery were restored in allogeneic IUT and TBI mice, as were antibody responses after TI challenge. Upon immunization with TD antigens, however, IUT and TBI mice exhibited suboptimal responses as measured by the capacity to isotype switch and generate germinal center (GC) B cells. Thus, although allogeneic BM transplantation results in complete recovery of the B-cell compartment, certain elements of the humoral response remain defective.

Entities:  

Mesh:

Year:  2002        PMID: 12393436     DOI: 10.1182/blood-2002-04-1232

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  TRAF6 is a critical regulator of LMP1 functions in vivo.

Authors:  Kelly M Arcipowski; Laura L Stunz; Gail A Bishop
Journal:  Int Immunol       Date:  2013-10-29       Impact factor: 4.823

2.  Latent membrane protein 1, the EBV-encoded oncogenic mimic of CD40, accelerates autoimmunity in B6.Sle1 mice.

Authors:  Anna L Peters; Laura L Stunz; David K Meyerholz; Chandra Mohan; Gail A Bishop
Journal:  J Immunol       Date:  2010-09-01       Impact factor: 5.422

3.  Anti-inflammatory effects of the neurotransmitter agonist Honokiol in a mouse model of allergic asthma.

Authors:  Melissa E Munroe; Thomas R Businga; Joel N Kline; Gail A Bishop
Journal:  J Immunol       Date:  2010-10-01       Impact factor: 5.422

4.  Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells.

Authors:  Jamie L Fornek; Lorraine T Tygrett; Thomas J Waldschmidt; Valeria Poli; Robert C Rickert; Geoffrey S Kansas
Journal:  Blood       Date:  2005-10-13       Impact factor: 22.113

5.  Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation.

Authors:  Ryan M Kelly; Steven L Highfill; Angela Panoskaltsis-Mortari; Patricia A Taylor; Richard L Boyd; Georg A Holländer; Bruce R Blazar
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

6.  TRAF binding is required for a distinct subset of in vivo B cell functions of the oncoprotein LMP1.

Authors:  Kelly M Arcipowski; Gail A Bishop
Journal:  J Immunol       Date:  2012-10-29       Impact factor: 5.422

7.  Hematopoietic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoietic stem cells.

Authors:  Marta Serafini; Scott J Dylla; Masayuki Oki; Yves Heremans; Jakub Tolar; Yuehua Jiang; Shannon M Buckley; Beatriz Pelacho; Terry C Burns; Sarah Frommer; Derrick J Rossi; David Bryder; Angela Panoskaltsis-Mortari; Matthew J O'Shaughnessy; Molly Nelson-Holte; Gabriel C Fine; Irving L Weissman; Bruce R Blazar; Catherine M Verfaillie
Journal:  J Exp Med       Date:  2007-01-16       Impact factor: 14.307

Review 8.  Experimental and clinical progress of in utero hematopoietic cell transplantation therapy for congenital disorders.

Authors:  Chunyu Shi; Lu Pan; Zheng Hu
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

Review 9.  In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application.

Authors:  Graça Almeida-Porada; Anthony Atala; Christopher D Porada
Journal:  Mol Ther Methods Clin Dev       Date:  2016-03-30       Impact factor: 6.698

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.